OSL’s Pancreatic Cancer Treatment Approved for Sale in Europe
Article Archived May 05, 2020
OncoSil Medical (ASX:OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer in the EU and UK.
